Related Experiment Video
Updated: Aug 14, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex--Part 2
Jeffrey T Kohrt1, Kevin J Filipski, Wayne L Cody
1Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. jeffrey.kohrt@pfizer.com
Abstract:
The activated factor VII/tissue factor complex (FVIIa/TF) is known to play a key role in the formation of blood clots. Inhibition of this complex may lead to new antithrombotic drugs. A fluoropyridine-based series of FVIIa/TF inhibitors was discovered which utilized a diisopropylamino group for binding in the S2 and S3 binding pockets of the active site of the enzyme complex. In this series, an enhancement in binding affinity was observed by substitution at the 5-position of the hydroxybenzoic acid sidechain. An X-ray crystal structure indicates that amides at this position may increase inhibitor binding affinity through interactions with the S1'/S2' pocket.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release

